BDNF (P21)

CognitiveNeurotrophic research peptideExperimental

Short research peptide discussed in nootropic communities as a BDNF-pathway probe (often overlapping the P21 / Cerebrolysin-derived peptide literature). Not FDA-approved.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): ~1,800 g/mol
Half-life: 1–2 hours
Unit: mcg
Administration Route: Subcutaneous
Frequency: Daily
Last updated: 8/23/2026
Targets: BDNF-related signaling (proposed)

Overview

Short research peptide discussed in nootropic communities as a BDNF-pathway probe (often overlapping the P21 / Cerebrolysin-derived peptide literature). Not FDA-approved.

Protocol

Dosage Range: 200–500 mcg
Frequency: Daily
Cycle: 6–8 weeks on, 2–4 off
Administration Route: Subcutaneous
Reconstitution Guide: 2 mL BAC for 10 mg vial

Science

Mechanism of Action

Claimed to enhance BDNF-related synaptic plasticity in preclinical reports related to CNTF/ADNP-derived fragments; independent human trials are lacking and commercial “P21” identity is inconsistent.